Research Details

NAD+ Scientific Research Overview Nicotinamide adenine dinucleotide, or NAD+, is an essential cellular coenzyme involved in oxidation-reduction reactions, energy metabolism, mitochondrial function, DNA-repair signaling, and the activity of NAD-dependent enzymes. Research interest in NAD+ has expanded considerably across cellular metabolism, aging biology, mitochondrial disorders, cardiovascular function, neurological conditions, and metabolic regulation. Direct research on administered NAD+ should be distinguished from research involving its precursors, including nicotinamide riboside and nicotinamide mononucleotide. Published Research Findings A 2019 human pilot study documented changes in circulating NAD+ and its metabolites during a controlled six-hour intravenous infusion. The study helped characterize how administered NAD+ was metabolized and excreted, but it was not designed to demonstrate anti-aging, cognitive, or performance outcomes. A randomized placebo-controlled study in patients with heart failure caused by ischemic cardiomyopathy reported improvements in selected cardiac-function measurements following a short course of intravenous NAD+ alongside standard medical care. Several secondary clinical outcomes favored NAD+, although not all outcome differences reached statistical significance. These disease-specific findings require replication and should not be generalized to healthy populations. A 2026 retrospective pilot comparing commercially administered intravenous NAD+ and nicotinamide riboside provided preliminary information about infusion tolerability and short-term safety. The investigators emphasized the need for controlled research because available direct evidence remains sparse. A 2026 systematic review concluded that human evidence for broad anti-aging and wellness outcomes remains inconsistent. The strongest data currently concern biological markers, pharmacokinetics, and selected disease-specific studies rather than proven extension of lifespan or healthspan. Evidence and Regulatory Context NAD+ is an essential endogenous molecule, but that does not automatically establish the safety or effectiveness of externally administered research formulations. Findings involving oral NAD+ precursors should not be presented as direct evidence for injectable NAD+. Research Links Human NAD+ Infusion and Metabolomic Pilot Study NAD+ in Ischemic Cardiomyopathy: Randomized Trial Intravenous NAD+ Versus Nicotinamide Riboside: Tolerability Pilot Systematic Review of NAD-Related Clinical Evidence 2026 Review of NAD+ Supplementation and Anti-Aging Evidence Research Context: Published findings summarized on this page involve controlled studies, pilot investigations, disease-specific clinical research, and different NAD-related formulations. Findings involving NADH, nicotinamide riboside, nicotinamide mononucleotide, or other precursors should not be assumed to apply directly to NAD+. These studies do not establish the identity, purity, sterility, safety, effectiveness, or regulatory status of the research material offered on this page. This product is sold strictly for lawful laboratory research and is not intended for human or veterinary use.